Entry - #614750 - MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13 - OMIM
# 614750

MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13


Alternative titles; symbols

MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 2; CMSTA2


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
11q23.3 Myasthenic syndrome, congenital, 13, with tubular aggregates 614750 AR 3 DPAGT1 191350
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
HEAD & NECK
Eyes
- Ptosis, mild (less common)
SKELETAL
Spine
- Scoliosis
MUSCLE, SOFT TISSUES
- Hypotonia
- Proximal muscle weakness
- Tubular aggregates seen on muscle biopsy
- Decreased AChR at the endplate
- Decreased postsynaptic folding at the neuromuscular junction
- Abnormal jitter seen on EMG
- Decremental response on 3-Hz repetitive nerve stimulation
NEUROLOGIC
Central Nervous System
- Delayed motor development
- Unsteady gait due to muscle weakness
LABORATORY ABNORMALITIES
- Hypoglycosylated serum transferrin
MISCELLANEOUS
- Onset in childhood (range 0.5 to 7 years)
- Slowly progressive
- Some patients show improvement in muscle power in the teenage years
- Favorable response to acetylcholinesterase inhibitors
MOLECULAR BASIS
- Caused by mutation in the dolichyl-phosphate N-acetylglucosamine phosphotransferase gene (DPAGT1, 191350.0002)
Myasthenic syndrome, congenital, with tubular aggregates - PS610542 - 3 Entries
Myasthenic syndrome, congenital - PS601462 - 32 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.33 Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects AR 3 615120 AGRN 103320
1p21.3 ?Myasthenic syndrome, congenital, 15, without tubular aggregates AR 3 616227 ALG14 612866
1q32.1 Myasthenic syndrome, congenital, 7B, presynaptic, autosomal recessive AR 3 619461 SYT2 600104
1q32.1 Myasthenic syndrome, congenital, 7A, presynaptic, and distal motor neuropathy, autosomal dominant AD 3 616040 SYT2 600104
2p21 Myasthenic syndrome, congenital, 22 AR 3 616224 PREPL 609557
2p13.3 Myasthenia, congenital, 12, with tubular aggregates AR 3 610542 GFPT1 138292
2q12.3 Myasthenic syndrome, congenital, 20, presynaptic AR 3 617143 SLC5A7 608761
2q31.1 Myasthenic syndrome, congenital, 1A, slow-channel AD 3 601462 CHRNA1 100690
2q31.1 Myasthenic syndrome, congenital, 1B, fast-channel AD, AR 3 608930 CHRNA1 100690
2q37.1 ?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency AR 3 616323 CHRND 100720
2q37.1 Myasthenic syndrome, congenital, 3B, fast-channel AR 3 616322 CHRND 100720
2q37.1 ?Myasthenic syndrome, congenital, 3A, slow-channel AD 3 616321 CHRND 100720
3p25.1 Myasthenic syndrome, congenital, 5 AR 3 603034 COLQ 603033
4p16.3 Myasthenic syndrome, congenital, 10 AR 3 254300 DOK7 610285
9q22.33 Myasthenic syndrome, congenital, 14, with tubular aggregates AR 3 616228 ALG2 607905
9q31.3 Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency AR 3 616325 MUSK 601296
10q11.23 Myasthenic syndrome, congenital, 6, presynaptic AR 3 254210 CHAT 118490
10q11.23 Myasthenic syndrome, congenital, 21, presynaptic AR 3 617239 SLC18A3 600336
10q22.1 Myasthenic syndrome, congenital, 19 AR 3 616720 COL13A1 120350
11p11.2 ?Myasthenic syndrome, congenital, 17 AR 3 616304 LRP4 604270
11p11.2 Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency AR 3 616326 RAPSN 601592
11q23.3 Myasthenic syndrome, congenital, 13, with tubular aggregates AR 3 614750 DPAGT1 191350
12p13.31 Myasthenic syndrome, congenital, 25 AR 3 618323 VAMP1 185880
15q23 Myasthenic syndrome, congenital, 24, presynaptic AR 3 618198 MYO9A 604875
17p13.2 Myasthenic syndrome, congenital, 4B, fast-channel AR 3 616324 CHRNE 100725
17p13.2 Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency AR 3 608931 CHRNE 100725
17p13.2 Myasthenic syndrome, congenital, 4A, slow-channel AD, AR 3 605809 CHRNE 100725
17p13.1 ?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency AR 3 616314 CHRNB1 100710
17p13.1 Myasthenic syndrome, congenital, 2A, slow-channel AD 3 616313 CHRNB1 100710
17q23.3 Myasthenic syndrome, congenital, 16 AR 3 614198 SCN4A 603967
20p12.2 ?Myasthenic syndrome, congenital, 18 AD 3 616330 SNAP25 600322
22q11.21 Myasthenic syndrome, congenital, 23, presynaptic AR 3 618197 SLC25A1 190315

TEXT

A number sign (#) is used with this entry because of evidence that congenital myasthenic syndrome-13 (CMS13) is caused by compound heterozygous mutation in the DPAGT1 gene (191350) on chromosome 11q23.


Description

Congenital myasthenic syndrome-13 (CMS13) is an autosomal recessive neuromuscular disorder characterized by onset of proximal muscle weakness in the first decade. EMG classically shows a decremental response to repeated nerve stimulation. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors (summary by Belaya et al., 2012).

For a discussion of genetic heterogeneity of CMS, see CMS1A (601462).


Clinical Features

Belaya et al. (2012) reported 5 patients from 4 families of European origin with limb-girdle congenital myasthenic syndrome with tubular aggregates on muscle biopsy. The age at onset ranged from 0.5 to 7 years. Presenting symptoms included difficulty walking and frequent falls, but younger patients showed hypotonia and poor head control. Proximal limb muscles were predominantly affected, although some distal muscle groups were also involved. There was minimal involvement of facial, ocular, and bulbar muscles, and only 1 patient had mild ptosis. Two developed scoliosis. Electrophysiologic studies indicated a disorder of the neuromuscular junction, including a decrement on 3-Hz repetitive nerve stimulation and jitter and blocking on single-fiber EMG. All patients benefited from anticholinesterase medication, and 2 showed a response with 3,4-diaminopyridine, which increases acetylcholine release from the nerve terminal. One of the patients had previously been reported by Slater et al. (2006). Muscle biopsy showed structural and functional abnormalities of the neuromuscular junction, including decreased acetylcholine receptor binding sites and decreased postsynaptic folding, consistent with a loss of endplate AChR. All patients reported by Belaya et al. (2012) had tubular aggregates on muscle biopsy, characterized as long membranous tubules packed with different misfolded and aggregated membrane proteins.


Inheritance

The transmission pattern of congenital myasthenic syndrome-13 in the families reported by Belaya et al. (2012) was consistent with autosomal recessive inheritance.


Molecular Genetics

In 5 patients from 4 families with congenital myasthenic syndrome-13, Belaya et al. (2012) identified 7 different mutations in the DPAGT1 gene (see, e.g., 191350.0002-191350.0006). All mutations were in compound heterozygous state. The first 4 mutations were identified by exome sequencing of 2 unrelated patients and were confirmed by Sanger sequencing. The mutations segregated with the disorder in those families with available material. In vitro studies showed that DPAGT1 is required for efficient glycosylation of AChR subunits and for efficient export of AChR receptors to the cell surface. The findings demonstrated the importance of N-linked protein glycosylation for proper functioning of the neuromuscular junction, and suggested that the primary pathogenic mechanism of DPAGT1 mutations is reduced levels of AChR at the endplate region. Laboratory studies of 2 patients showed abnormal glycosylation of transferrin, consistent with a functional defect of DPAGT1. Belaya et al. (2012) postulated that the defect in glycosylation of certain proteins may lead to misfolding and aggregation in the sarcoplasmic reticulum, resulting in formation of tubular aggregates within muscle tissue.


REFERENCES

  1. Belaya, K., Finlayson, S., Slater, C. R., Cossins, J., Liu, W. W., Maxwell, S., McGowan, S. J., Maslau, S., Twigg, S. R. F., Walls, T. J., Pascual Pascual, S. I., Palace, J., Beeson, D. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am. J. Hum. Genet. 91: 193-201, 2012. [PubMed: 22742743, images, related citations] [Full Text]

  2. Slater, C. R., Fawcett, P. R. W., Walls, T. J., Lyons, P. R., Bailey, S. J., Beeson, D., Young, C., Gardner-Medwin, D. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 129: 2061-2076, 2006. [PubMed: 16870884, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 7/30/2012
alopez : 03/17/2023
carol : 01/30/2018
carol : 04/27/2015
ckniffin : 4/21/2015
carol : 8/2/2012
ckniffin : 8/1/2012

# 614750

MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13


Alternative titles; symbols

MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 2; CMSTA2


ORPHA: 353327, 590;   DO: 0110676;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
11q23.3 Myasthenic syndrome, congenital, 13, with tubular aggregates 614750 Autosomal recessive 3 DPAGT1 191350

TEXT

A number sign (#) is used with this entry because of evidence that congenital myasthenic syndrome-13 (CMS13) is caused by compound heterozygous mutation in the DPAGT1 gene (191350) on chromosome 11q23.


Description

Congenital myasthenic syndrome-13 (CMS13) is an autosomal recessive neuromuscular disorder characterized by onset of proximal muscle weakness in the first decade. EMG classically shows a decremental response to repeated nerve stimulation. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors (summary by Belaya et al., 2012).

For a discussion of genetic heterogeneity of CMS, see CMS1A (601462).


Clinical Features

Belaya et al. (2012) reported 5 patients from 4 families of European origin with limb-girdle congenital myasthenic syndrome with tubular aggregates on muscle biopsy. The age at onset ranged from 0.5 to 7 years. Presenting symptoms included difficulty walking and frequent falls, but younger patients showed hypotonia and poor head control. Proximal limb muscles were predominantly affected, although some distal muscle groups were also involved. There was minimal involvement of facial, ocular, and bulbar muscles, and only 1 patient had mild ptosis. Two developed scoliosis. Electrophysiologic studies indicated a disorder of the neuromuscular junction, including a decrement on 3-Hz repetitive nerve stimulation and jitter and blocking on single-fiber EMG. All patients benefited from anticholinesterase medication, and 2 showed a response with 3,4-diaminopyridine, which increases acetylcholine release from the nerve terminal. One of the patients had previously been reported by Slater et al. (2006). Muscle biopsy showed structural and functional abnormalities of the neuromuscular junction, including decreased acetylcholine receptor binding sites and decreased postsynaptic folding, consistent with a loss of endplate AChR. All patients reported by Belaya et al. (2012) had tubular aggregates on muscle biopsy, characterized as long membranous tubules packed with different misfolded and aggregated membrane proteins.


Inheritance

The transmission pattern of congenital myasthenic syndrome-13 in the families reported by Belaya et al. (2012) was consistent with autosomal recessive inheritance.


Molecular Genetics

In 5 patients from 4 families with congenital myasthenic syndrome-13, Belaya et al. (2012) identified 7 different mutations in the DPAGT1 gene (see, e.g., 191350.0002-191350.0006). All mutations were in compound heterozygous state. The first 4 mutations were identified by exome sequencing of 2 unrelated patients and were confirmed by Sanger sequencing. The mutations segregated with the disorder in those families with available material. In vitro studies showed that DPAGT1 is required for efficient glycosylation of AChR subunits and for efficient export of AChR receptors to the cell surface. The findings demonstrated the importance of N-linked protein glycosylation for proper functioning of the neuromuscular junction, and suggested that the primary pathogenic mechanism of DPAGT1 mutations is reduced levels of AChR at the endplate region. Laboratory studies of 2 patients showed abnormal glycosylation of transferrin, consistent with a functional defect of DPAGT1. Belaya et al. (2012) postulated that the defect in glycosylation of certain proteins may lead to misfolding and aggregation in the sarcoplasmic reticulum, resulting in formation of tubular aggregates within muscle tissue.


REFERENCES

  1. Belaya, K., Finlayson, S., Slater, C. R., Cossins, J., Liu, W. W., Maxwell, S., McGowan, S. J., Maslau, S., Twigg, S. R. F., Walls, T. J., Pascual Pascual, S. I., Palace, J., Beeson, D. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am. J. Hum. Genet. 91: 193-201, 2012. [PubMed: 22742743] [Full Text: https://doi.org/10.1016/j.ajhg.2012.05.022]

  2. Slater, C. R., Fawcett, P. R. W., Walls, T. J., Lyons, P. R., Bailey, S. J., Beeson, D., Young, C., Gardner-Medwin, D. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 129: 2061-2076, 2006. [PubMed: 16870884] [Full Text: https://doi.org/10.1093/brain/awl200]


Creation Date:
Cassandra L. Kniffin : 7/30/2012

Edit History:
alopez : 03/17/2023
carol : 01/30/2018
carol : 04/27/2015
ckniffin : 4/21/2015
carol : 8/2/2012
ckniffin : 8/1/2012